利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

268 条记录 (耗时 0.09 秒)

    Means for diagnosing tumours
    51.
    发明申请
    Means for diagnosing tumours 审中-公开
    手段诊断肿瘤

    公开(公告)号：US20040048317A1

    公开(公告)日：2004-03-11

    申请号：US10362843

    申请日：2003-07-29

    发明人： Elke Pogge Von Strandmann

    IPC分类号： C12Q001/68 ,  G01N033/574 ,  C07K016/30

    CPC分类号： G01N33/57484 ,  C12Q1/6886 ,  G01N33/573 ,  G01N33/574

    摘要： The invention relates to a means for diagnosing tumours, especially malignant tumours in the human body and the animal body, using at least one substance which interacts with DCoH for in vitro diagnosis.

    摘要翻译： 本发明涉及使用至少一种与DCoH相互作用的物质进行体外诊断来诊断肿瘤，特别是人体和动物体内的恶性肿瘤的手段。

    Novel antibodies reactive with human carcinomas
    52.
    发明申请
    Novel antibodies reactive with human carcinomas 审中-公开
    新型抗体与人类癌反应

    公开(公告)号：US20040043029A1

    公开(公告)日：2004-03-04

    申请号：US10336672

    申请日：2003-01-02

    申请人： Bristol-Myers Squibb Company

    发明人： Ingegerg Hellstrom ,  Karl Erik Hellstrom ,  Kim Folger Bruce ,  George J. Schreiber

    IPC分类号： A61K039/395 ,  C12N005/06 ,  C07K016/30

    CPC分类号： G01N33/57484 ,  A61K38/00 ,  A61K47/6809 ,  A61K47/6811 ,  A61K47/6829 ,  A61K47/6851 ,  A61K49/0058 ,  A61K51/1045 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/415 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2319/00 ,  C12N15/10

    摘要： The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(abnull)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(abnull)2-LysPE40 and ChiBR96 Fabnull-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

    摘要翻译： 本发明涉及与人癌细胞反应的新型抗体，抗体片段和抗体缀合物和单链免疫毒素。 更具体地，本发明的抗体，缀合物和单链免疫毒素包括：鼠单克隆抗体BR96; 人/鼠嵌合抗体，ChiBR96; BR96的F（ab'）2片段; ChiBR96-PE，ChiBR96-LysPE40，ChiBR96F（ab'）2-LysPE40和ChiBR96 Fab'-LysPE40缀合物和重组BR96sFv-PE40免疫毒素。 这些分子与人类癌症表面的细胞膜抗原反应。 BR96抗体及其功能等同物对癌细胞显示出高度的选择性，并具有介导抗体依赖性细胞毒性和补体依赖性细胞毒活性的能力。 此外，本发明的抗体内在于它们结合的癌细胞内，因此特别可用于治疗应用，例如作为抗体药物或抗体 - 毒素缀合物的抗体组分。 抗体还具有独特的特征，因为当以指定浓度以未修饰的形式使用时，它们是细胞毒性的。

    Polyclonal antibodies against fibrinogen degradation products and associated methods of production and use
    53.
    发明申请
    Polyclonal antibodies against fibrinogen degradation products and associated methods of production and use 审中-公开
    针对纤维蛋白原降解产物的多克隆抗体及相关生产和使用方法

    公开(公告)号：US20040033544A1

    公开(公告)日：2004-02-19

    申请号：US10457901

    申请日：2003-06-09

    发明人： That T. Ngo

    IPC分类号： G01N033/574 ,  C12P021/04 ,  C07K016/30

    CPC分类号： G01N33/57484 ,  A61K2039/505 ,  C07K16/065 ,  C07K16/3076 ,  G01N33/574 ,  G01N2333/75

    摘要： Monospecific polyclonal fibrinogen degradation product antibodies, their method of use, the methods to detect cancer and for monitoring the progress of anticancer treatment by immunochemically measuring the quantity of serum FDP in serum are disclosed. The present invention teaches that monospecific polyclonal FDP antibodies that bind to human fibrinogen degradation products (nullFDPnull) can be obtained by inoculating a laboratory animal with human FDP or human FDP derivatives to induce the production in the inoculated laboratory animal of at least one monospecific polyclonal antibody that binds to human FDP and isolating the monospecific polyclonal antibody. By generating anti-serum to FDP from immunogens and purifying said immunogens using affinity chromatography, increased levels of production of FDP antibodies over the prior art are achieved. A method for screening cancer is disclosed comprising contacting biological sample obtained from a patient with at least one monospecific polyclonal FDP antibody that binds to mammalian FDP. A method is also disclosed for producing a quantitative enzyme linked immunosorbent assay (ELISA) for serum FDP by using monospecific polyclonal antibodies that bind to human FDP.

    摘要翻译： 公开了单特异性多克隆纤维蛋白原降解产物抗体，其使用方法，检测癌症的方法和通过免疫化学测量血清中血清FDP的量来监测抗癌治疗进展。 本发明教导了结合人纤维蛋白原降解产物（“FDP”）的单特异性多克隆FDP抗体可以通过用人FDP或人FDP衍生物接种实验室动物来诱导在接种的实验室动物中产生至少一种单特异性 结合人FDP并分离单特异性多克隆抗体的多克隆抗体。 通过从免疫原产生抗血清至FDP并使用亲和层析纯化所述免疫原，实现了比现有技术更高水平的FDP抗体产生。 公开了一种用于筛选癌症的方法，包括将从患者获得的生物样品与至少一种与哺乳动物FDP结合的单特异性多克隆FDP抗体接触。 还公开了通过使用与人FDP结合的单特异性多克隆抗体来生产血清FDP的定量酶联免疫吸附测定（ELISA）的方法。

    Cancer diagnosis and assays for screening anti-cancer agents
    55.
    发明申请
    Cancer diagnosis and assays for screening anti-cancer agents 审中-公开
    用于筛选抗癌剂的癌症诊断和测定

    公开(公告)号：US20040028684A1

    公开(公告)日：2004-02-12

    申请号：US10276016

    申请日：2002-11-12

    发明人： Matthias Georg Christian Gstaiger ,  Wilhelm Krek

    IPC分类号： A61K039/395 ,  C07K014/705 ,  C07K016/30

    CPC分类号： G01N33/574 ,  A61K38/00 ,  C07K14/47

    摘要： A novel RMP homologue is provided, as well as nucleic acids encoding the protein and antisense nucleic acids, Methods of diagnosing conditions dependent on RMP are provided as well as screening methods for identify agents active against conditions dependent on RMP, such as conditions dependent on amino acid regulation, cancer, neurodegeneration, muscle degeneration, immune disorders, and AIDS.

    摘要翻译： 提供了一种新的RMP同源物，以及编码蛋白质和反义核酸的核酸，提供了依赖于RMP的病症诊断方法，以及鉴定对依赖于RMP的病症有活性的筛选方法，例如依赖于氨基酸的病症 酸调节，癌症，神经变性，肌肉变性，免疫疾病和艾滋病。

    MHC-peptide complex binding ligands
    60.
    发明申请
    MHC-peptide complex binding ligands 审中-公开
    MHC-肽复合物结合配体

    公开(公告)号：US20030223994A1

    公开(公告)日：2003-12-04

    申请号：US10371942

    申请日：2003-02-20

    发明人： Henricus Renerus Jacobus Mattheus Hoogenboom ,  Yoram Reiter

    IPC分类号： G01N033/53 ,  G01N033/567 ,  C07H021/04 ,  A61K039/395 ,  C12P021/02 ,  C12N005/06 ,  C07K016/30

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K16/2833 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55

    摘要： Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.

    摘要翻译： 公开了包含免疫球蛋白重链可变（VH）结构域和免疫球蛋白轻链可变（VL）结构域的蛋白质配体，其中所述蛋白质结合包含MHC和肽的复合物，在不存在结合的情况下基本上不结合MHC 肽，并且在不存在MHC的情况下基本上不结合肽，并且该肽是gp100，MUC1，TAX或hTERT的肽片段。 还公开了使用和鉴定这种配体的方法。